Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/oncotarget.16014 http://scihub22266oqcxt.onion/10.18632/oncotarget.16014 C5601165!5601165!28947997     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Oncotarget 2017 ; 8 (36): 60589-604 Nephropedia Template TP {{tp|p=28947997|t=2017. Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions |pdf=|usr=}}{{28947997}} gab.com Text Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=28947997 #FOAvip Gastrointestinal stromal tumors (GISTs) are the most common sarcomas in humans. Constitutively activating mutations in the KIT or PDGFRA receptor tyrosine kinases are the initiating oncogenic events. Most metastatic GISTs respond dramatically to therapies with KIT/PDGFRA inhibitors. Asymptomatic and mitotically-inactive KIT/PDGFRA-mutant ?microGISTs? are found in one third of adults, but most of these small tumors never progress to malignancy, underscoring that a progression of oncogenic mutations is required. Recent studies have identified key genomic abnormalities in GIST progression. Novel insights into the genetic progression of GISTs are shedding new light on therapeutic innovations. Twit Text FOAVip Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=28947997 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28947997 #FOAvip English Wikipedia <ref>{{Cite pmid|28947997}}</ref> Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions #MMPMID28947997 Li K; Cheng H; Li Z; Pang Y; Jia X; Xie F; Hu G; Cai Q; Wang Y Oncotarget 2017[Sep]; 8 (36): 60589-604 PMID28947997show ga Gastrointestinal stromal tumors (GISTs) are the most common sarcomas in humans. Constitutively activating mutations in the KIT or PDGFRA receptor tyrosine kinases are the initiating oncogenic events. Most metastatic GISTs respond dramatically to therapies with KIT/PDGFRA inhibitors. Asymptomatic and mitotically-inactive KIT/PDGFRA-mutant ?microGISTs? are found in one third of adults, but most of these small tumors never progress to malignancy, underscoring that a progression of oncogenic mutations is required. Recent studies have identified key genomic abnormalities in GIST progression. Novel insights into the genetic progression of GISTs are shedding new light on therapeutic innovations. äGenetic progression in gastrointestinal stromal tumors: mechanisms and(epmc).pdf DeepDyve Pubget Overpricing